Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Anbesol liquid
1203040C0BDAAAC
|
Anbesol (Mouthwash) | Cetylpyridinium chloride | Ear, Nose and Oropharynx | 214 |
|
Boots Antiseptic 0.025% gel
1203040C0BHAAAF
|
Boots (Cetylpyridinium chloride) | Cetylpyridinium chloride | Ear, Nose and Oropharynx | No data available |
|
Boots Oral Antiseptic 0.025% mouthwash
1203040C0BCAAAB
|
Boots Oral Antiseptic | Cetylpyridinium chloride | Ear, Nose and Oropharynx | No data available |
|
Cetylpyridinium chloride 0.025% gel
1203040C0AAAFAF
|
Cetylpyridinium chloride (Mouthwash) | Cetylpyridinium chloride | Ear, Nose and Oropharynx | No data available |
|
Cetylpyridinium chloride 0.025% mouthwash sugar free
1203040C0AAABAB
|
Cetylpyridinium chloride (Mouthwash) | Cetylpyridinium chloride | Ear, Nose and Oropharynx | No data available |
|
Cetylpyridinium chloride 1.4mg lozenges
1203030D0AAAAAA
|
Cetylpyridinium chloride (Antiseptic lozenges) | Cetylpyridinium chloride | Ear, Nose and Oropharynx | No data available |
|
Generic Anbesol liquid
1203040C0AAACAC
|
Cetylpyridinium chloride (Mouthwash) | Cetylpyridinium chloride | Ear, Nose and Oropharynx | No data available |
|
Germolene 0.025% antiseptic gel
1203040C0BIAAAF
|
Germolene (Cetylpyridinium chloride) | Cetylpyridinium chloride | Ear, Nose and Oropharynx | No data available |
|
Merocets 1.4mg lozenges
1203030D0BBAAAA
|
Merocets | Cetylpyridinium chloride | Ear, Nose and Oropharynx | No data available |
|
Merocets Plus lozenges
1203030D0BFAAA0
|
Merocets Plus | Cetylpyridinium chloride | Ear, Nose and Oropharynx | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.